Table 4 Summary of Patient Characteristics by DMT Parameters
TR% | TR (°C) | |||||||
|---|---|---|---|---|---|---|---|---|
Characteristics | N | Mean ± SD | Median (Range) | p-value002A | N | Mean ± SD | Median (Range) | p-value* |
Age | ||||||||
<60 | 15 | -0.17 ± 0.95 | -0.24 (-1.95, 2.01) | 0.392 | 15 | -0.05 ± 0.31 | -0.08 (-0.63, 0.66) | 0.421 |
>60 | 11 | -0.01 ± 1.44 | 0.38 (-2.69, 2.02) | 11 | -0.02 ± 0.47 | 0.13 (-0.91, 0.63) | ||
Sex | ||||||||
Male | 17 | 0.19 ± 1.02 | 0.04 (-1.7, 2.02) | 0.125 | 17 | 0.06 ± 0.33 | 0.01 (-0.54, 0.66) | 0.112 |
Female | 9 | -0.66 ± 1.26 | -0.51 (-2.69, 1.09) | 9 | -0.22 ± 0.42 | -0.18 (-0.91, 0.37) | ||
Smoker | ||||||||
No | 9 | 0.42 ± 1.09 | 0.51 (-1.6, 2.02) | 0.090 | 9 | 0.13 ± 0.35 | 0.17 (-0.53, 0.63) | 0.100 |
Yes | 17 | -0.38 ± 1.13 | -0.19 (-2.69, 2.01) | 17 | -0.12 ± 0.37 | -0.06 (-0.91, 0.66) | ||
Length of Stay | ||||||||
<5 | 12 | -0.18 ± 1.39 | 0.19 (-2.69, 2.01) | 0.797 | 12 | -0.06 ± 0.46 | 0.07 (-0.91, 0.66) | 0.758 |
>5 | 14 | -0.04 ± 0.98 | -0.16 (-1.95, 2.02) | 14 | -0.02 ± 0.31 | -0.05 (-0.63, 0.63) | ||
Obesity | ||||||||
No | 16 | -0.27 ± 1.28 | -0.14(-2.69, 2.01) | 0.429 | 16 | -0.09 ± 0.42 | -0.05 (-0.91, 0.66) | 0.493 |
Yes | 10 | 0.17 ± 0.93 | -0.08 (-1.43, 2.02) | 10 | 0.05 ± 0.30 | -0.03 (-0.47, 0.63) | ||
Chemotherapy | ||||||||
No | 13 | -0.27 ± 0.93 | -0.04 (-1.7, .79) | 0.663 | 13 | -0.09 ± 0.30 | -0.01 (-0.54, 0.26) | 0.663 |
Yes | 13 | 0.06 ± 1.37 | -0.12 (-2.69, 2.02) | 13 | 0.01 ± 0.45 | -0.04 (-0.91, 0.66) | ||
Radiotherapy | ||||||||
No | 15 | -0.57 ± 1.11 | -0.24 (-2.69, .79) | 0.052 | 15 | -0.19 ± 0.36 | -0.08 (-0.91, 0.26) | 0.052 |
Yes | 11 | 0.54 ± 0.93 | 0.26 (-.41, 2.02) | 11 | 0.17 ± 0.29 | 0.09 (-0.14, 0.66) | ||
ASA Score | ||||||||
2 | 2 | -0.46 ± 1.37 | -0.46 (-1.43, .51) | ** | 2 | -0.15 ± 0.45 | -0.15 (-0.47, 0.17) | ** |
3 | 24 | -0.07 ± 1.17 | -0.08 (-2.69, 2.02) | 24 | -0.03 ± 0.38 | -0.03 (-0.91, 0.66) | ||
Lee Cardiac Risk Index | ||||||||
2 | 25 | -0.13 ± 1.18 | -0.12 (-2.69, 2.02) | ** | 25 | -0.05 ± 0.38 | -0.04 (-0.91, 0.66) | ** |
3 | 1 | 0.51 ± NA | 0.51(.51, .51) | 1 | 0.17 ± NA | 0.17 (0.17, 0.17) | ||
ACC/AHA Risk Score | ||||||||
≤2 | 23 | -0.13 ± 1.23 | -0.19 (-2.69, 2.02) | ** | 23 | -0.05 ± .4 | -0.06 (-0.91, 0.66) | ** |
>2 | 2 | 0.23 ± 0.39 | 0.24 (-.04, .51) | 3 | 0.04 ± .11 | -0.01 (-0.04, 0.17) | ||
Diabetes Mellitus | ||||||||
No | 23 | -0.12 ± 1.23 | -0.04 (-2.69, 2.02) | ** | 23 | -0.04 ± 0.40 | -0.01 (-0.91, 0.66) | ** |
Yes | 3 | 0.05 ± 0.40 | -0.12 (-.24, .51) | 3 | 0.02 ± 0.13 | -0.04 (-0.08, 0.17) | ||
Hypertension | ||||||||
No | 12 | -0.45 ± 1.04 | -0.25 (-2.69, .79) | 0.165 | 12 | -0.15 ± 0.35 | -0.08 (-0.91, 0.26) | 0.181 |
Yes | 14 | 0.20 ± 1.21 | 0.19 (-1.95, 2.02) | 14 | 0.06 ± 0.39 | 0.07 (-0.63, 0.66) | ||
Hyperlipidemia | ||||||||
No | 17 | -0.23 ± 1.09 | -0.12 (-2.69, 2.02) | 0.467 | 17 | -0.08 ± 0.36 | -0.04 (-0.91, 0.63) | 0.435 |
Yes | 9 | 0.14 ± 1.32 | 0.38 (-1.95, 2.01) | 9 | 0.04 ± 0.42 | 0.13 (-0.63, 0.66) | ||
Statin Therapy | ||||||||
No | 20 | -0.24 ± 1.14 | -0.16 (-2.69, 2.02) | 0.301 | 20 | -0.08 ± 0.36 | -0.05 (-0.91, 0.63) | 0.273 |
Yes | 6 | 0.34 ± 1.23 | 0.45 (-1.6, 2.01) | 6 | 0.12 ± 0.41 | 0.15 (-0.53, 0.66) | ||
ACE-Inhibitor Therapy | ||||||||
No | 23 | -0.13 ± 1.23 | -0.12 (-2.69, 2.02) | ** | 23 | -0.05 ± 0.40 | -0.04 (-0.91, 0.66) | ** |
Yes | 3 | 0.10 ± 0.38 | 0.04 (-0.24, 0.51) | 3 | 0.03 ± 0.13 | 0.01 (-0.08, 0.17) | ||
AT2-Inhibitor Therapy | ||||||||
No | 25 | -0.05 ± 1.15 | -0.04 (-2.69, 2.02) | ** | 25 | -0.02 ± 0.37 | -0.01 (-0.91, 0.66) | ** |
Yes | 1 | -1.43 ± NA | -1.43 (-1.43, -1.43) | 1 | -0.47 ± NA | -0.47 (-0.47, -0.47) | ||
Beta-Blocker Therapy | ||||||||
No | 20 | -0.22 ± 1.23 | -0.07 (-2.69, 2.02) | 0.503 | 20 | -0.08 ± 0.40 | -0.03 (-0.91,0 .63) | 0.465 |
Yes | 6 | 0.30 ± 0.89 | -0.08 (-0.31, 2.01) | 6 | 0.10 ± 0.29 | -0.03 (-0.10, 0.66) | ||